Skip to content

INDEPENDENT EQUITY RESEARCH

  • The Program
  • Reports
  • About Us
  • Contact us
  • The Program
  • Reports
  • About Us
  • Contact us
  • The Program
  • Reports
  • About Us
  • Contact us

INDEPENDENT EQUITY RESEARCH

Read more about the article Oramed has a sufficient cash balance to fund its clinical development timeline in the near term; several clinical milestones are scheduled for 2018 and 2019; stock target price remains at NIS 53.2.
Oramed Pharmaceuticals (PRNewsFoto/Oramed Pharmaceuticals Inc)

Oramed has a sufficient cash balance to fund its clinical development timeline in the near term; several clinical milestones are scheduled for 2018 and 2019; stock target price remains at NIS 53.2.

  • Post author:jaimeuss_admin
  • Post published:6 בSeptember 2018
  • Post category:Research

Continue ReadingOramed has a sufficient cash balance to fund its clinical development timeline in the near term; several clinical milestones are scheduled for 2018 and 2019; stock target price remains at NIS 53.2.
INDEPENDENT EQUITY RESEARCH

Tel: +972(0)9.950.2888
Email: [email protected]

Contact us

Copyright © 2020 Frost & Sullivan. All Rights Reserved.   Privacy Policy.

Accessibility by WAH